drugset / Trial / NCT05901051

High-dose Dual Therapy with Different Administration Frequencies

NCT05901051

Phase 4 Completed 327 enrolled Shanghai Jiao Tong University School of Medicine
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is a single center, randomized controlled clinical study. The enrolled patients are HP positive. They are diagnosed as HP positive by rapid urease test and/or 13C urea breath test. According to the declaration of Helsinki, 327 patients will be included in this study. After obtaining the written informed consent of the patients, HP culture and drug sensitivity test will be conducted on all the selected patients with the success rate, adverse reactions, compliance, antibiotic resistance of HP and its impact on HP eradication.

Timeline

Start
2021-03-30
Primary completion
2023-09-10
Completion
2023-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Amoxicillin Other / unclassified 0.75 g
Subject Amoxicillin Other / unclassified 1 g
Background Vonoprazan Other / unclassified 20 mg